Skip to content

Kovai Medical Center & Hospital Limited (KOVAI)

Small Cap

Pharma stocks · Small cap · NSE

Kovai Medical Center & Hospital Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹5,875
-98.00 · -1.64%
Market cap ₹6,524 Cr
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm IST
Details
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:42 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens

Trend score and candlestick chart

64Bullish

SMA20 -1.4% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)

Stock trend: 42
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%

FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence

Technical chart

KOVAID candles · FIT view+7.1%
Latest close ₹5875.00 on 2026-10-19

Daily history is available from 2026-04-20; the requested 1Y window is partially covered.

Bar
-1.3%
RSI
39
MACD hist
-6.22
52W pos
51%
Visible chart range
Candle interval
2026-10-19O ₹5950.00H ₹6012.00L ₹5874.00C ₹5875.00Vol 4,319 sh
₹5.22k₹5.54k₹5.86k₹6.18k₹6.50k52H52L₹5875.002026-032026-06VolRSIMACD2026-042026-062026-072026-092026-11
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

KOVAINifty PharmaNifty 500
-9%-3%+2%+8%20 Jul1 Sept19 Oct19 Oct 2026KOVAI -0.9%Nifty Pharma -1.5%Nifty 500 -5.6%
KOVAI
-0.9%
Nifty 500
-5.6%
Nifty Pharma
-1.5%
Vs Nifty 500
+4.7 pp
Chart stats
19 Oct 2026
From 52W high
-8.8%
₹6,444
52W range position
51%
₹5,275.5 - ₹6,444
ATR (14)
2.0%
₹118
Volume vs 20D
1.16x
Latest completed session
Avg traded value
₹2.3 Cr
20-session average
20D price channel
₹5,848 - ₹6,334.5
8.9% annualized volatility
Research snapshot

What the evidence says now

Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.

Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE
46

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Latest result
Excellent
80

Revenue +15.2% · PAT +21.1% YoY

Technical
Bullish
64

Price trend and sector-relative-strength timing.

Valuation
Legacy model
-146.4%

Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.

Trust
Limited evidence
80

Financial-only signal; management claim evidence is not sufficient yet.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Latest result

Quarter ended 30 Jun 2026

Excellent · 80/100

Rev +15% YoY · PAT +21% YoY · margin expansion · operating leverage

Filed 30 Jun 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹431 Cr+15.2%+4.1%
EBITDA₹124 Cr+17.0%+11.7%
Operating margin29.0%+100 bps+200 bps
PAT₹69 Cr+21.1%+9.5%
PAT margin16.0%+77 bps+79 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E
113.00
P/B
22.59
EV/EBITDA
41.26
Market Cap
6524.00Cr

Profitability

ROE
22.20%
ROCE
24.10%
ROA
9.57%
Dividend Y
0.25%

Growth (CAGR)

Revenue 5Y
15.00%
EPS 5Y
23.00%
Revenue 3Y
14.00%
EPS 3Y
15.00%

Balance Sheet

Debt/Equity
0.70
Interest Coverage
9.92×
Altman Z
8.49
Book Value
264.00

Cash Flow

FCF Yield
—
FCF Positive Y
4/5
OCF
87.00 Cr
EPS TTM
52.99

Shareholding

Promoter Hold
56.53%
Promoter Pledge
0.00%
Momentum 52W
56%

Financial History

Updated 20/10/2026

Revenue

₹ Cr
Latest: 1,586+15.7% vs prev
01586Mar 2017: 531Mar 2018: 588Mar 2019: 628Mar 2020: 712Mar 2021: 690Mar 2022: 905Mar 2023: 1,020Mar 2024: 1,220Mar 2025: 1,371Mar 2026: 1,586FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Net Profit

₹ Cr
Latest: 244+16.7% vs prev
0244.0Mar 2017: 60.0Mar 2018: 58.0Mar 2019: 60.0Mar 2020: 95.0Mar 2021: 78.0Mar 2022: 104Mar 2023: 116Mar 2024: 180Mar 2025: 209Mar 2026: 244FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Return on Equity

%
Latest: 18.5-3.8% vs prev
025.5Mar 2017: 25.5%Mar 2018: 20.2%Mar 2019: 17.5%Mar 2020: 22.0%Mar 2021: 15.3%Mar 2022: 17.1%Mar 2023: 16.1%Mar 2024: 20.3%Mar 2025: 19.2%Mar 2026: 18.5%FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Neutral

Trend is undirectional — long-term trend unclear. RSI 39.

  • SMA20 falling (~1.4% over last month) — short-term momentum negative.
  • RSI(14) at 39 — sideways, no extreme reading.
  • MACD below signal but histogram contracting — bearish momentum easing.
  • 9% off 52W high · 11% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

66
RS percentile
Insufficient history
1M return
-5.6%
3M return
-0.9%
6M return
+4.2%
1Y return
-
RS 1D
0
RS 20D
-
Sector rank
#1
Industry rank
#17
Stage evidence
  • At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
127 observations
19 Oct 2026Value 111.06-0.62%
9610110611011520 Apr19 Jun18 Aug19 Oct111
RS vs Nifty 500111

Valuation & peers

U-Score 46 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies

46U-SCORE
Premium Compounder

Fundamental score breakdown

U band · FAIR VALUE
Valuation0/30
Growth14/25
Quality15/20
Balance Sheet8/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
46

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

46/100 · legacy band FAIR VALUE

Positive drivers

  • Piotroski is strong at 8/9.
  • Quality contributes 15/20 to the score.
  • Growth contributes 14/25 to the score.

Main drags

  • Fair-value margin of safety is negative at -146.4%.
  • Valuation is weaker at 0/30; verify the latest quarterly trend.
  • Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
113.0
PB
22.6
EV/EBITDA
41.3
ROE
22.2%
ROCE
24.1%
FCF Yield
—
Debt/Equity
0.7
MoS
-146.4%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
46
Previous: 46
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-146.4%
Previous: -146.4%

Score history

12 stored score snapshots. Latest stored move: +0 points.

20 Oct 2026
v4.3-runtime-valuation
46
46
46
46
46
46
46
46
46
46
46
46

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number
₹561.04
-947.2% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹2,384.55
-146.4% MoS
PEG
5.71

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 166
35
48.2
13.4%
-2%
WATCHLIST
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 166
33
320.0
1.5%
-846%
WATCHLIST
MOREPENLAB
Small
Morepen Laboratories Limited
Healthcare Services
match 164
20
63.1
5.3%
-1007%
OVERVALUED
RPGLIFE
Small
RPG Life Sciences Limited
Healthcare Services
match 164
57
41.0
19.3%
+13%
FAIR VALUE
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 164
35
43.7
14.3%
-27%
WATCHLIST

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Kovai Medical Center & Hospital Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score
80Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 87th percentile within Pharma. No major sub-score weakness stands out.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026
management-trust-v1
8 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank
90th percentile

overall median 67 · Pharma: 87th pctile, median 70 · Small: 92nd pctile, median 66

Evidence depth
Financial-only

8 documents have extracted text, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
80
strong · capital discipline
Results
95
strong · quarterly consistency

Trust positives

  • ▸Promoter holding is 56.5%.
  • ▸Promoter pledge is zero.
  • ▸4 years of positive FCF.
  • ▸ROCE is 24.1%.

Trust risks

  • ▸ROCE trend is -2.6%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

7 shown
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Aug - We enclose herewith the copies of Newspaper Advertisement published in English and Tamil in the "Trinity mirror" and "Makkal Kural" respectively, with regard to the …

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Jun - We enclose the copies of Newspaper Advertisement published in English and Tamil on 29.06.2026 with regard to the 40th Annual General meeting Notice to Shareholders.

Source: Bse

Open source ↗
Announcement

Announcement under Regulation 30 (LODR)-Demise 7 Jun - Dr. Thavamani Devi Palaniswami, KMCH Joint Managing Director, died on 06.06.2026 and ceased as promoter.

Source: Bse

Open source ↗
Announcement

Submission Of Revised Financial Results Due To An Inadvertent Arithmetical Error In The Tax Expense For The Quarter Ended 31St March,2026 26 May

Source: Bse

Open source ↗
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.